抗ウイルス薬
11/30, MRK, COVID-19
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate ― If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World ― U.K.’s Medicines and Healthcare Products Regulatory Agency Authorizes Molnupiravir for the Treatment of Mild-to-Moderate COVID-19 in Adults With a Positive SARS-CoV-2 Diagnostic Test
抗体医薬
Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
- メルクとリッジバックが開発中の経口抗ウイルス薬モルヌピラビルに対してFDA諮問委員会は13対10で肯定的な票決を下した。
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
- メルクとリッジバックは開発中の経口抗ウイルス薬モルヌピラビルを重症化リスクのあるCOVID-19軽~中等症の成人に投与したムーブアウト試験の最新成績を発表した。
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
- ファイザーは米国政府に対して開発中の経口抗ウイルス薬候補を提供し、COVID-19との戦いを支援する。
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
- ファイザーと医薬品特許プール(MPP)は低~中所得国における経口抗ウイルス薬候補へのアクセスを拡大するために特許権の使用許諾契約を締結した。
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate ― If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2
- ファイザーは新規のCOVID-19経口抗ウイルス薬候補の緊急使用許可を申請した。承認されるとPAXLOVID(PF-07321332;リトナビル)はSAR-CoV-2を標的としてデザインされた初の3CLプロテアーゼ阻害薬となる。
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
- ファイザーの新規のCOVID-19経口抗ウイルス治療薬候補はフェーズ 2/3試験EPIC-HRの中間解析において入院または死亡のリスクを89%減少した。
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World ― U.K.’s Medicines and Healthcare Products Regulatory Agency Authorizes Molnupiravir for the Treatment of Mild-to-Moderate COVID-19 in Adults With a Positive SARS-CoV-2 Diagnostic Test
- メルクとリッジバックは経口抗ウイルス薬モルヌピラビルの世界で初めての承認を取得 ― 英国の医薬品・医療用品規制庁(MHRA)がSARS-CoV-2診断検査陽性の中等症から重症の成人COVID-19患者に対する治療薬として承認した。
抗体医薬
11/18, AZN, COVID-19
New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
ワクチン
New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention
- AZD7442はCOVID-19高リスク集団における 2本のフェーズ3試験の解析により安定した有効性と長期の予防効果が確認された。
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
- GSKとVirバイオテクノロジーはCOVID-19治療薬ソトロビマブの米国政府との購入契約を発表した。
Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
- COVID-19の早期治療として筋肉注射によるソトロビマブの投与を評価したフェーズ3試験COMET-TAILにおいて主要評価項目が達成された。
ワクチン